Literature DB >> 8656011

Human immunodeficiency virus type 1 (HIV-1)--and Epstein-Barr virus--specific cytotoxic T lymphocyte precursors exhibit different kinetics in HIV-1--infected persons.

A M Geretti1, M E Dings, C A van Els, C A van Baalen, F J Wijnholds, J C Borleffs, A D Osterhaus.   

Abstract

The frequencies of human immunodeficiency virus type 1 (HIV-1) Gag- and Epstein-Barr virus (EBV)-specific cytotoxic T lymphocyte precursors (CTLp) were studied longitudinally in peripheral blood mononuclear cells from 9 HIV-1-infected persons. By antigen-specific stimulation, HIV-1 Gag-specific CTLp were detected in vitro throughout the course of HIV-1 infection, even after the onset of overt disease. In 4 patients, however, HIV-1 Gag-specific CTLp frequencies declined over time in the presence of maintained EBV-specific CTLp. This decline was correlated with decreasing CD4 (r = .38; P < .05) and CD8 (r = .75; P < .001) cell numbers. The maintenance of EBV-specific CTLp in patients with low CD4 cell numbers indicated that EBV-specific CTL-mediated immunity may remain longer unaffected by HIV-1-induced immune dysfunction. Consistent with this observation, the growth of EBV-specific CTL could be supported in vitro by EBV-infected lymphoblastoid B cell lines, independent of both CD4 cells and exogenous cytokines.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8656011     DOI: 10.1093/infdis/174.1.34

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  8 in total

1.  Longitudinal phenotypic analysis of human immunodeficiency virus type 1-specific cytotoxic T lymphocytes: correlation with disease progression.

Authors:  G S Ogg; S Kostense; M R Klein; S Jurriaans; D Hamann; A J McMichael; F Miedema
Journal:  J Virol       Date:  1999-11       Impact factor: 5.103

2.  Identification of type-specific cytotoxic T lymphocyte responses to homologous viral proteins in laboratory workers accidentally infected with HIV-1.

Authors:  N V Sipsas; S A Kalams; A Trocha; S He; W A Blattner; B D Walker; R P Johnson
Journal:  J Clin Invest       Date:  1997-02-15       Impact factor: 14.808

3.  Human immunodeficiency virus type 1- and cytomegalovirus-specific cytotoxic T lymphocytes can persist at high frequency for prolonged periods in the absence of circulating peripheral CD4(+) T cells.

Authors:  H M Spiegel; G S Ogg; E DeFalcon; M E Sheehy; S Monard; P A Haslett; G Gillespie; S M Donahoe; H Pollack; W Borkowsky; A J McMichael; D F Nixon
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

4.  Enhancing of anti-viral activity against HIV-1 by stimulation of CD8+ T cells with thymic peptides.

Authors:  H Müller; G Mayer; B Behnke; E Heimüller; G Hamscher; D Immler; C Siethoff; H E Meyer; M Schreiber
Journal:  Clin Exp Immunol       Date:  1999-07       Impact factor: 4.330

5.  Epstein-Barr virus-specific cytotoxic T cell responses in HIV-1 infection: different kinetics in patients progressing to opportunistic infection or non-Hodgkin's lymphoma.

Authors:  M J Kersten; M R Klein; A M Holwerda; F Miedema; M H van Oers
Journal:  J Clin Invest       Date:  1997-04-01       Impact factor: 14.808

6.  Functional impairment of simian immunodeficiency virus-specific CD8+ T cells during the chronic phase of infection.

Authors:  T U Vogel; T M Allen; J D Altman; D I Watkins
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

7.  Neutralization assay using a modified vaccinia virus Ankara vector expressing the green fluorescent protein is a high-throughput method to monitor the humoral immune response against vaccinia virus.

Authors:  Antonio Cosma; Silja Bühler; Rashmi Nagaraj; Caroline Staib; Anna-Lena Hammarin; Britta Wahren; Frank D Goebel; Volker Erfle; Gerd Sutter
Journal:  Clin Diagn Lab Immunol       Date:  2004-03

8.  Early impairment of CD8+ T cells immune response against Epstein-Barr virus (EBV) antigens associated with high level of circulating mononuclear EBV DNA load in HIV infection.

Authors:  Jérôme Legoff; Corinne Amiel; Olivier Calisonni; Delphine Fromentin; Bakoliarisoa Rajoely; Nisen Abuaf; Eric Tartour; Willy Rozenbaum; Laurent Bélec; Jean-Claude Nicolas
Journal:  J Clin Immunol       Date:  2004-03       Impact factor: 8.317

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.